A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity
← catalyst calendarNCT07767175 · readout in 400 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
142estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-12 | estimated | When the study began enrolling |
| Primary completion | 2027-09-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-23 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Overweight
- Obesity
Interventions
- Drug: NNC0721-8060
- Drug: Semaglutide
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPart A: Number of treatment emergent adverse events (TEAE)
measured From Day 1 to Day 36
Part B: Number of treatment emergent adverse events (TEAE)
measured From Day 1 to Day 57
Part C: Change from baseline in body weight
measured From Day 1 to Day 85
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed